BURLINGAME, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced the closing of its underwriters’ over-allotment for 749,846 shares of its common stock at a price of $4.00 per share resulting in gross proceeds of approximately $3.0 million before customary underwriting discounts and offering-related expenses. Through the closing of its initial public offering on May 22, 2016 and the over-allotment shares issued today, Pulse has issued an aggregate of 5,749,846 shares of common stock resulting in net proceeds to the company of $20,250,000. All of the shares were offered by Pulse Biosciences. 

MDB Capital Group and Feltl and Company acted as the joint book-running managers for the initial public offering.

A registration statement relating to the securities sold was declared effective by the Securities and Exchange Commission on May 13, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Pulse Biosciences

Pulse Biosciences is a medical device company developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling, or NPES. NPES has been shown in pre-clinical data to provide effective local tumor control and to initiate an adaptive immune response. Pulse Biosciences intends to deploy its NPES platform across a variety of applications, including human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide comparable benefits. More information is available at www.pulsebiosciences.com.

Contact:
Brian Dow
Chief Financial Officer
ir@pulsebiosciences.com